Brief: Genprex Announces First Patient Dosed In Phase 1/2 Acclaim-1 Clinical Trial Of Reqorsa™ Immunogene Therapy In Combination With Tagrisso® To Treat Non-Small Cell Lung Cancer
02/03/2022 14:04
March 2 (Reuters) - Genprex Inc GNPX.O :
* GENPREX ANNOUNCES FIRST PATIENT DOSED IN PHASE 1/2
ACCLAIM-1
CLINICAL TRIAL OF REQORSA™ IMMUNOGENE THERAPY IN COMBINATION
WITH TAGRISSO® TO TREAT NON-SMALL CELL LUNG CANCER
Source text for Eikon: ID:nBw8C53FPa
Further company coverage: GNPX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Genprex
See all newsBrief: Genprex Announces Collaboration With Roche Diagnostics For Biomarker Assay Validation Studies
NASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: Genprex Announces Ip Australia's Intent To Grant Patent For Reqorsa® Gene Therapy